Cargando…
Angiotensin receptor-neprilysin inhibitor for the treatment of heart failure: a review of recent evidence
Heart failure (HF) is a growing health concern in aging societies worldwide. Sacubitril/valsartan is changing the real-world treatment in the whole spectrum of HF. The beginning was the PARADIGM-HF trial published in 2014, which demonstrated the beneficial effects of inhibiting natriuretic peptide b...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Association of Internal Medicine
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7214374/ https://www.ncbi.nlm.nih.gov/pubmed/32392658 http://dx.doi.org/10.3904/kjim.2020.105 |